Wedbush downgraded Blueprint Medicines (BPMC) to Neutral from Outperform with a $129 price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
- Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila
- Blueprint Medicines Announces Merger Agreement with Sanofi
- Sanofi to acquire Blueprint Medicines for $129 per share in cash
- Sanofi acquires Blueprint Medicines for $129 per share or $9.1B